How would you approach a young patient with oligometastatic inflammatory triple negative breast cancer with bone only metastases?

There is no clinical trial data to provide solid guidance on how to manage oligometastatic de novo stage IV disease. We learned that surgery to the primary tumor without ablating distant mets and giving multidrug adjuvant-like systemic therapy does not improve survival. We also learned that SBRT to ...

When answering this question, I am mindful of the data from EA2108 (Khan et al., PMID 34995128). This trial included some (not many) triple negative breast cancer patients (n=20). For this group, Khan et al. reported and clearly depicted in their data supplement that OS was significantly worse in th...

Inflammatory Breast Cancer (IBC) is a heterogeneous disease with variant molecular subtypes associated with distinct prognostic outcomes as other common breast cancers. Systemic therapies such as endocrine therapy and anti-HER2 targeted therapy can be as effective as chemotherapy immunotherapy.

In a ...